1. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. (December 2019) Authors: Thunnissen, E.; Lissenberg-Witte, B.I.; van den Heuvel, M.M.; Monkhorst, K.; Skov, B.G.; Sørensen, J.B.; Mellemgaard, A.; Dingemans, A.M.C.; Speel, E.J.M.; de Langen, A.J.; Hashemi, S.M.S.; Bahce, I.; van der Drift, M.A.; Looijen-Salamon, M.G.; Gosney, J.; Postmus, P.E.; Samii, S.M.S.; Duplaquet,... Journal: Lung cancer Issue: Volume 138(2019) Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. Issue 9 (28th December 2015) Authors: Nabholtz, J.M.; Chalabi, N.; Radosevic‐Robin, N.; Dauplat, M.M.; Mouret‐Reynier, M.A.; Van Praagh, I.; Servent, V.; Jacquin, JP; Benmammar, K.E.; Kullab, S.; Bahadoor, M.R.K.; Kwiatkowski, F.; Cayre, A.; Abrial, C.; Durando, X.; Bignon, Y.J.; Chollet, P.; Penault‐Llorca, F. Journal: International journal of cancer Issue: Volume 138:Issue 9(2016:May 01) Page Start: 2274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma. (January 2021) Authors: Biau, J.; Thivat, E.; Chautard, E.; Stefan, D.; Boone, M.; Chauffert, B.; Bourgne, C.; Richard, D.; Molnar, I.; Levesque, S.; Bellini, R.; Kwiatkowski, F.; Karayan-Tapon, L.; Verrelle, P.; Godfraind, C.; Durando, X. Journal: Radiotherapy and oncology Issue: Volume 154(2021) Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗